266 related articles for article (PubMed ID: 22025213)
1. Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.
Valdez KE; Fan F; Smith W; Allred DC; Medina D; Behbod F
J Pathol; 2011 Dec; 225(4):565-73. PubMed ID: 22025213
[TBL] [Abstract][Full Text] [Related]
2. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.
Hong Y; Limback D; Elsarraj HS; Harper H; Haines H; Hansford H; Ricci M; Kaufman C; Wedlock E; Xu M; Zhang J; May L; Cusick T; Inciardi M; Redick M; Gatewood J; Winblad O; Aripoli A; Huppe A; Balanoff C; Wagner JL; Amin AL; Larson KE; Ricci L; Tawfik O; Razek H; Meierotto RO; Madan R; Godwin AK; Thompson J; Hilsenbeck SG; Futreal A; Thompson A; Hwang ES; Fan F; Behbod F;
J Pathol; 2022 Feb; 256(2):186-201. PubMed ID: 34714554
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
4. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
5. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.
Lee S; Stewart S; Nagtegaal I; Luo J; Wu Y; Colditz G; Medina D; Allred DC
Cancer Res; 2012 Sep; 72(17):4574-86. PubMed ID: 22751464
[TBL] [Abstract][Full Text] [Related]
6. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
[TBL] [Abstract][Full Text] [Related]
7. Everolimus Inhibits the Progression of Ductal Carcinoma
Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
[TBL] [Abstract][Full Text] [Related]
8. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
9. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
10. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
11. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.
Behbod F; Kittrell FS; LaMarca H; Edwards D; Kerbawy S; Heestand JC; Young E; Mukhopadhyay P; Yeh HW; Allred DC; Hu M; Polyak K; Rosen JM; Medina D
Breast Cancer Res; 2009; 11(5):R66. PubMed ID: 19735549
[TBL] [Abstract][Full Text] [Related]
12. Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.
Russell TD; Jindal S; Agunbiade S; Gao D; Troxell M; Borges VF; Schedin P
Am J Pathol; 2015 Nov; 185(11):3076-89. PubMed ID: 26343330
[TBL] [Abstract][Full Text] [Related]
13. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Hutten SJ; de Bruijn R; Lutz C; Badoux M; Eijkman T; Chao X; Ciwinska M; Sheinman M; Messal H; Herencia-Ropero A; Kristel P; Mulder L; van der Waal R; Sanders J; Almekinders MM; Llop-Guevara A; Davies HR; van Haren MJ; Martin NI; Behbod F; Nik-Zainal S; Serra V; van Rheenen J; Lips EH; Wessels LFA; ; Wesseling J; Scheele CLGJ; Jonkers J
Cancer Cell; 2023 May; 41(5):986-1002.e9. PubMed ID: 37116492
[TBL] [Abstract][Full Text] [Related]
14. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.
Horimoto Y; Terao T; Tsutsumi Y; Tanabe M; Mogushi K; Hlaing MT; Sasaki R; Saeki H; Okazaki M; Sonoue H; Arakawa A; Saito M
Am J Surg Pathol; 2019 Sep; 43(9):1221-1228. PubMed ID: 31192864
[TBL] [Abstract][Full Text] [Related]
15. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
16. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
17. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
18. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
[TBL] [Abstract][Full Text] [Related]
19. Progression from ductal carcinoma in situ to invasive breast cancer: revisited.
Cowell CF; Weigelt B; Sakr RA; Ng CK; Hicks J; King TA; Reis-Filho JS
Mol Oncol; 2013 Oct; 7(5):859-69. PubMed ID: 23890733
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]